Branded

Altuviiio is an injectable medicine used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).

Lilly also will automatically cap out-of-pocket costs at $35 at participating retail pharmacies for people with commercial insurance using Lilly insulin.

Austedo XR is indicated for the treatment of chorea associated with Huntington’s disease and the treatment of tardive dyskinesia in adults.

Jemperli is now also indicated to treat patients with recurrent or advanced mismatch repair-deficient endometrial cancer.

​​​​​​​Trodelvy is now approved for pre-treated HR+/HER2- metastatic breast cancer.

Tezspire is now approved for self-administration in a pre-filled, single-use pen for patients aged 12 years old and older with severe asthma.

Orserdu (elacestrant) is the first and only treatment specifically indicated for patients with ESR1 Mutations in ER+, HER2- advanced or metastatic breast cancer.

Keytruda is now approved as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 centimeters [cm]), II, or IIIA non-small cell lung cancer.